Helsinn announces European Commission approval of the liquid formulation of AKYNZEO® (fosnetupitant/palonosetron)
December 02, 2021 04:30 ET
|
Helsinn Healthcare S.A.
Helsinn announces European Commission approval of the liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) Lugano, Switzerland, December 2, 2021 – Helsinn Group, a fully integrated, global...
Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD
June 24, 2021 08:30 ET
|
Helsinn Healthcare S.A.
Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD Lugano, Switzerland, June 24, 2021 – Helsinn, a Swiss Biopharmaceutical...
Helsinn appoints Mary Lynne Hedley to Board of Directors
April 29, 2021 03:00 ET
|
Helsinn Healthcare S.A.
Lugano, Switzerland, April 29, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne...
Helsinn appoints Mary Lynne Hedley to Board of Directors
April 29, 2021 03:00 ET
|
Helsinn Healthcare S.A.
Lugano, Switzerland, April 29, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne...
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting
March 18, 2021 08:30 ET
|
Helsinn Healthcare S.A.
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting Lugano, Switzerland, March 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on...
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
January 12, 2021 03:30 ET
|
Helsinn Healthcare S.A.
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Lugano, Switzerland, January 12, 2021 – Helsinn, a Swiss...
Helsinn Advanced Synthesis opens its largest dedicated Anticancer bay
July 30, 2020 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn Advanced Synthesis opens its largest dedicated Anticancer bay Biasca, Switzerland, July 30, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare...
Helsinn announces launch of oral formulation of Akynzeo® in China
June 09, 2020 03:30 ET
|
Helsinn Healthcare S.A.
Helsinn announces launch of oral formulation of Akynzeo® in China Lugano, Switzerland, June 9, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease...
Helsinn Group announces FDA approval of a new liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) injection in the United States
June 02, 2020 08:30 ET
|
Helsinn Healthcare S.A.
Helsinn Group announces FDA approval of a new liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) injection in the United States Lugano, Switzerland, June 2, 2020 – Helsinn, a Swiss...
Helsinn supported ‘70 Years of Cancer Care in China’ celebratory event in Shanghai
November 14, 2019 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn supported ‘70 Years of Cancer Care in China’ celebratory event in Shanghai Lugano, Switzerland, November 14, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer...